NEW YORK (GenomeWeb News) – Trovagene said in a regulatory filing today that it has entered into a deal with Illumina to evaluate the possible integration of Trovagene's transrenal technology with Illumina's sequencing technology.
Specifically, the two firms will assess Trovagene's technology for the isolation, extraction, and genetic analysis of nucleic acids from urine, according to a document filed with the US Securities and Exchange Commission. Trovagene's technology is based on a proprietary method for isolating short, fragmented nucleic acids, it said on its website. The firm has also developed "ultra-short" amplicon assays for detecting transrenal nucleic acids, and developed PCR-based genetic and mutation panels.
All results from its agreement with Illumina will be shared between the parties, and the deal, which was reached on June 20, will terminate either 30 days after the completion of the evaluation of the technologies, or on the one-year anniversary of the agreement, whichever comes first, unless extended by mutual agreement.
Financial and other terms were not disclosed.